NIKKEI 225
38,054.13 -502.74 (-1.30%) HANG SENG
18,230.19 -246.82 (-1.34%) CRUDE OIL
78.00 -1.23 (-1.55%) GOLD FUTURES
2,363.50 -0.60 (-0.03%) DOW
38,146.53 -295.01 (-0.77%) BTC-GBP
54,440.96 +1,606.93 (+3.04%)
Avenue Therapeutics, Inc. (ATXI)
| Previous close | 3.7300 |
| Open | 3.7300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.6500 - 3.8107 |
| 52-week range | 3.5160 - 93.7500 |
| Volume | |
| Avg. volume | 63,721 |
| Market cap | 3.435M |
| Beta (5Y monthly) | -0.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1,145.7300 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.25 |
GlobeNewswireAvenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“
- GlobeNewswire
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024. “The first quarter was incredibly p
- GlobeNewswire
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock. The exercised warrants are comprised of warrants to purchase sh
